Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (TN25)

March 13, 2024 updated by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a two-arm, double-blind, multicenter clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in individuals with new onset T1D to determine whether rituximab-pvvr followed by abatacept results in an improvement in the AUC C-Peptide during a MMTT compared to Rituximab-pvvr alone at 24 months. Additional aims will compare the safety, tolerability in the two treatment arms as well as other clinical metabolic measures: exogenous insulin use, hemoglobin A1c, time in range from continuous glucose monitors, and severe hypoglycemia. Exploratory studies will assess changes in immune markers.

Study Type

Interventional

Enrollment (Estimated)

74

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Australia
    • Victoria
      • Melbourne, Victoria, Australia, 3050
        • Recruiting
        • Walter and Eliza Hall Institute of Medical Research
        • Contact:
        • Principal Investigator:
          • John Wentworth, MD
  • United States
    • California
      • Palo Alto, California, United States, 94304
        • Recruiting
        • Stanford University
        • Contact:
        • Principal Investigator:
          • Priya Pahalad, MD
      • San Francisco, California, United States, 94158
        • Recruiting
        • University of California San Francisco
        • Principal Investigator:
          • Stephen Gitelman, MD
        • Contact:
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • Barbara Davis Center for Childhood Diabetes
        • Principal Investigator:
          • Peter Gottlieb, MD
        • Contact:
    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Recruiting
        • Yale University
        • Contact:
        • Principal Investigator:
          • Jennifer Sherr, MD
    • Florida
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Indiana University - Riley Hospital for Children
        • Principal Investigator:
          • Linda DiMeglio, MD
        • Contact:
    • Kansas
      • Kansas City, Kansas, United States, 64114
        • Recruiting
        • The Children's Mercy Hospital
        • Principal Investigator:
          • Wayne Moore, MD
        • Contact:
    • New York
      • New York, New York, United States, 10032
        • Recruiting
        • Columbia University
        • Principal Investigator:
          • Robin Goland, MD
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15224
        • Recruiting
        • University of Pittsburg
        • Contact:
        • Principal Investigator:
          • Ingrid Libman, MD
    • South Dakota
      • Sioux Falls, South Dakota, United States, 57105
        • Recruiting
        • Sanford Children's Specialty Clinic
        • Contact:
        • Principal Investigator:
          • Kurt Griffin, MD, PhD
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Recruiting
        • Vanderbilt Eskind Diabetes Center
        • Contact:
        • Principal Investigator:
          • William Russell, MD
    • Texas
    • Washington
      • Seattle, Washington, United States, 98101
        • Recruiting
        • Benaroya Research Institute
        • Principal Investigator:
          • Sandra Lord, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years and older (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥ 8 and ≤ 45 years old at time of signing informed consent.
  2. Fulfill the ADA criteria for diagnosis of T1D within 100 days of randomization.
  3. Must be willing to provide informed consent or assent with a parent or legal guardian providing informed consent if < 18 years of age.
  4. Positive for at least one islet cell autoantibody; GAD65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A
  5. Must have stimulated C-peptide of ≥0.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days after the diagnosis of diabetes.
  6. Enrollees must be willing to comply with intensive diabetes management.
  7. Body weight must be ≥ 20.0 kg for study agent administration.
  8. Subjects who are CMV and/or EBV seronegative at screening must be CMV and/or EBV PCR negative and may not have had signs or symptoms of a CMV and/or EBV compatible illness prior to randomization.
  9. Female participants with reproductive potential must have a negative pregnancy test at screening and be willing to avoid pregnancy for the duration of treatment and until 3 months after the last dose of Abatacept. Female participants with reproductive potential who are sexually active will be instructed to use a highly effective contraceptive method until one year after the last dose of rituximab-pvvr.
  10. Male participants of reproductive age must use an adequate contraceptive method for the duration of rituximab-pvvr treatment and 12 months following the last dose of rituximab-pvvr.

  11. The following additional inclusion criteria regarding vaccines must be met:

    1. More than 4 weeks from immunization with a live viral vaccine
    2. Be up to date on all recommended vaccinations based on age of subject*
    3. Receive non-live influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available
    4. Up to date, including eligible boosters as indicated for COVID-19 with an authorized non-live COVID-19 vaccination at least two weeks prior to randomization.
    5. Willingness to forgo vaccines (other than killed influenza) during the 6 months after the rituximab-pvvr treatment period
  12. Participants must be willing to practice public health prevention measures such as social distancing, masking, and good hand hygiene, and/or receive therapeutics such as monoclonal antibodies and antivirals as directed by the study and recommended by local health authorities to prevent SARS-Cov-2 infection.
  13. Willing to wear a continuous glucose monitoring device for a minimum of 10 days every 6 months * Adult subjects must be fully immunized. Pediatric subjects who have not completed their primary vaccination schedule must receive all vaccinations allowable per local public health immunization guidelines for their current age prior to study drug delivery. Any remaining vaccinations should be given and continue per the schedule at least 6 months after rituximab-pvvr is administered.

Exclusion Criteria:

  1. One or more screening laboratory values as stated:

    1. Leukocytes <3,000/μL
    2. Neutrophils <1,500/μL
    3. Lymphocytes <800/μL
    4. Platelets <100,000/μL
    5. Hemoglobin <6.2 mmol/L (10.0 g/dL)
    6. Potassium >5.5 mmol/L or <3.0 mmol/L
    7. Sodium >150 mmol/L or <130 mmol/L
    8. AST or ALT ≥ 2.5 times the upper limits of normal
    9. Bilirubin ≥ 1.5 times upper limit of normal
  2. History of immune deficiency
  3. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening visit.
  4. Chronic active infection other than localized skin infections.
  5. Have active signs or symptoms of acute infection at the time of randomization.
  6. Have IgG and/or IgM levels below the normal reference ranges.
  7. Positive PPD, interferon gamma release assay (IGRA) or history of previous treatment for TB.
  8. Vaccination with a live virus within 4 weeks prior to initiating study treatment.
  9. A history of confirmed infectious mononucleosis within the 3 months prior to initiating study treatment, as documented by EBV serology (EBV VCA-IgM and VCA-IgG; PCR would be confirmatory).
  10. Laboratory evidence of current or past HIV or Hepatitis B or active Hepatitis C infection.
  11. Be currently pregnant, lactating or anticipate pregnancy within 14 weeks of the last study drug administration (Visit 15).
  12. Chronic use of oral or inhaled steroids or other immunosuppressive agents.
  13. Known and untreated hypothyroidism or active Graves' disease at randomization.
  14. History of malignancy.
  15. Prior treatment with active study agent from a previous clinical trial.
  16. Any laboratory abnormality or condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the participant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Rituximab-pvvr followed by Abatacept

Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study.

Abatacept will be given by a subcutaneous formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL).
Drug: Rituximab-pvvr
All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart.
Other Names:
  • Ruxience
Drug: Abatacept
Participants in the active drug arm will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL).
Other Names:
  • Orencia
Placebo Comparator: Rituximab-pvvr followed by Placebo

Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study.

Placebo will be given by a subcutaneous isotonic saline formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be match to active comparator, determined by weight: Up to 25 kg: 0.4 mL; 25 to <50 kg rec 0.7 mL, and > 50 kg receive 1.0 mL.
Drug: Rituximab-pvvr
All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart.
Other Names:
  • Ruxience
Drug: Sterile Sodium Chloride
Participants in the placebo arm will receive initial placebo injection at Week 16 of trial. Saline Placebo will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing volume be will determined according to weight to match active comparator: Up to 25 kg: 0.4 mL; 25 to <50 kg receive 0.7 mL and > 50 kg receive 1.0 mL.
Other Names:
  • 0.9% Sodium Chloride Water for Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
C-Peptide Response to 2-hr MMTT at 24 months post-randomization
Time Frame: 48-months from Day 0
The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab compared to those participants treated with Rituximab and placebo 24 months after enrollment.
48-months from Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
C-peptide AUC Means
Time Frame: Day 0 and every 6 months to trial end (up to 4 years)
C-peptide AUC Mean at 0, 6, 12, 18, 24, 30, 36, 42 and 48 months using the ANCOVA model.
Day 0 and every 6 months to trial end (up to 4 years)
Analysis of changes in immune responses to known diabetes antigens and a neoantigen over time by treatment group
Time Frame: Day 0, month 2, 4, 5, 6, 12, 13, 18, 24, 25, 30, and 36
Analysis of changes in immune responses to known diabetes antigens and a neoantigen. The investigators will compare the effects of drug treatments on the titers of autoantibodies: anti-insulin, anti-GAD65, anti-IA-2, anti-ZnT8. The investigators will also compare the effects of drug treatments on the response to Keyhole Limpet Hemocyanin (KLH) for which standardized immunological responses have been characterized.
Day 0, month 2, 4, 5, 6, 12, 13, 18, 24, 25, 30, and 36

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborators

National Institutes of Health (NIH)

Investigators

  • Study Chair: Stephen Gitelman, MD, Type 1 Diabetes TrialNet
  • Study Director: Kevan Herold, MD, Type 1 Diabetes TrialNet Chairman
  • Study Chair: Daniel Moore, MD, Type 1 Diabetes TrialNet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 30, 2023

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

October 1, 2029

Study Registration Dates

First Submitted

May 16, 2018

First Submitted That Met QC Criteria

April 23, 2019

First Posted (Actual)

April 29, 2019

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

December 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Rituximab-pvvr and Abatacept
  • UC4DK117009 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes Mellitus

Clinical Trials on Rituximab-pvvr

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe